Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 12/20 | 0.44 |
| ▸ | CSGALNACT1 | Q8TDX6 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.34 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1761958 | 1.00 | DGAT1 (0.44) | DGAT1CSGALNACT1CA2CA1FPR2 | |
| Trifluoroacetic Acid SCHEMBL1761480 | 0.98 | DGAT1 (0.42) | DGAT1CSGALNACT1CA2CA1FPR2 | |
| Trifluoroacetic Acid SCHEMBL1761478 | 0.98 | DGAT1 (0.42) | DGAT1CSGALNACT1CA2CA1FPR2 | |
| SCHEMBL1761707 | 0.92 | DGAT1 (0.52) | DGAT1CSGALNACT1 | |
| SCHEMBL1761482 | 0.91 | DGAT1 (0.37) | DGAT1CSGALNACT1CTPS1KIF11ALOX5AP | |
| Trifluoroacetic Acid SCHEMBL1761668 | 0.90 | DGAT1 (0.50) | DGAT1CSGALNACT1 | |
| SCHEMBL1761823 | 0.90 | DGAT1 (0.39) | DGAT1CSGALNACT1CTPS1KIF11 | |
| SCHEMBL1762005 | 0.90 | DGAT1 (0.53) | DGAT1CSGALNACT1CA2CA1AGTR2 | |
| SCHEMBL1762003 | 0.90 | DGAT1 (0.53) | DGAT1CSGALNACT1CA2CA1AGTR2 | |
| SCHEMBL1761423 | 0.88 | DGAT1 (0.55) | DGAT1CSGALNACT1CA2CA1FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118302-A1 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-05-19 | — | — | US | claimed |
| EP-1805156-B1 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-12-22 | — | — | EP | claimed |
| US-7759376-B2 | Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2010-07-20 | — | — | US | claimed |
| US-20070265298-A1 | Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-11-15 | — | — | US | claimed |
| US-20110118302-A1 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118302-A1 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| US-7759376-B2 | Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759376-B2 | Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2010-07-20 | — | — | US | disclosed |
| US-20070265298-A1 | Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070265298-A1 | Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265298-A1 | Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity | FABP4, GPR119, PGC | DGAT1 486/4885CSGALNACT1 3157/4885CA2 3327/4885 |
| US-20110118302-A1 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | FABP4, GPR119, PGC | DGAT1 486/4885CSGALNACT1 3157/4885CA2 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.